skip to navigation skip to content
search
  • About us
    • Who we are
    • Horizon scanning
    • Public involvement
      • Public Involvement Network Advisory Group
      • Patient group partners
      • Public partners
    • Policies & publications
    • Minutes
    • Meetings
    • Register for a meeting
    • ILAP
    • Latest update
      • HIS website survey
      • Speeding up access to new medicines in Scotland: abbreviated process
      • International Collaboration
      • Joint statement: NICE and SMC/HIS collaboration
      • NICE draft recommendations published on the use of treatments for COVID-19
      • Healthcare Improvement Scotland
      • NICE and SMC/HIS collaboration on health technology appraisal of therapeutics for COVID-19
      • Her Majesty Queen Elizabeth II
      • April 2022 decisions news release
      • New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines
      • December 2021 decisions news release
      • November 2021 decisions news release
      • March 2023 decisions news release
      • SMC publishes a Collaborative Advice Document for treatments for COVID-19
      • Public Partner Advert
      • Fast Track Resubmission Process
      • NICE issues final draft guidance for nirmatrelvir plus ritonavir for treating COVID-19 (partial review of TA878)
    • Contact us
  • Medicines advice
  • How we decide
    • PACE
    • Interim acceptance decision option
    • Ultra-orphan medicines for extremely rare conditions
    • Abbreviated submissions
  • Making a submission
Pills image

Policies & publications

  • Home
  • /
  • About us
  • /
  • Policies & publications

SMC guides and reports

General overview guides and reports on our work

  • A guide to the Scottish Medicines Consortium (PDF, 3MB)
  • SMC update report (PDF, 2MB)
  • Guide For Patient Group Partners 2022 (PDF, 1MB)

SMC policies

Policies relating to our processes and procedures

  • Modifiers (PDF, 158KB)
  • Biosimilar medicines (PDF, 223KB)
  • Guide to quality adjusted life years (QALYs) (PDF, 425KB)
  • Process for issuing not recommended advice due to non-submission (PDF, 100KB)
  • Company disagreement on medicines not validated as ultra-orphan.pdf (PDF, 313KB)

SMC policies: company submissions

Our policies and procedures around submissions made by pharmaceutical companies

  • NDC Health Economics checklist (DOCX, 156KB)
  • NDC Clinical checklist (DOCX, 172KB)
  • Release of company data (PDF, 563KB)
  • Consultation with competitor companies (PDF, 183KB)

Revised process for ultra-orphan medicines

Following the Scottish Government's announcement in June 2018 a new approach to the assessment of ultra-orphan medicines has been introduced.

Find out more

Declarations of interest

Declarations of interest for SMC are aligned with Healthcare Improvement Scotland Evidence Directorate policies.

Click the link to view the definitions and policies.

Scottish Government policies

Policies set by Scotland's devolved government

  • The introduction and availability of medicines (PDF, 142KB)
  • Safe and effective use of new medicines (PDF, 116KB)
  • Contact us
  • Register for a meeting
  • Newsletter sign up
  • Accessibility
  • Terms and conditions
  • Respecting your privacy
  • Freedom of information

© Scottish Medicines Consortium

  • NHS Scotland Logo